Reference Method for Broth Dilution Antifungal Susceptibility Testing

[Guest guest]

Have no idea what this means, but found it interesting. Method for

determining susceptibility to fungal infections.

Sharon

Posted : Fri, 16 May 2008 13:06:52 GMT

Author : PA-CLSI Category : Press Release

(http://feeds.earthtimes.org/earthtimes/pressrelease) Press Release News |

_Home_

(http://www.earthtimes.org/)

WAYNE, Pa. - (Business Wire) With the increased incidence of

systemic fungal infections and the growing number of antifungal agents,

laboratory

methods to guide the selection of antifungal therapy have gained greater

attention. Clinical and Laboratory Standards Institute (CLSI) has recently

published an updated standard, _Reference Method for Broth Dilution Antifungal

Susceptibility Testing of Filamentous Fungi; Approved Standard—Second

Edition_

(http://www.clsi.org/source/orders/index.cfm?section=Online_Store & ETask=1 & Task=1\

&

SEARCH_TYPE=FIND & FindIn=0 & FindSpec=m38) _ (M38-A2)_

(http://www.clsi.org/source/orders/index.cfm?section=Online_Store & ETask=1 & Task=1\

& SEARCH_TYPE=FIND & FindI

n=0 & FindSpec=m38) , which describes a method for testing the susceptibility

of filamentous fungi (moulds) that cause invasive (Aspergillus spp., Fusarium

spp., Rhizopus oryzae [R. arrhizus], Pseudallescheria boydii [scedosporium

apiospermum], S. prolificans, Sporothrix schenckii, and other opportunistic

pathogenic moulds) and cutaneous (dermatophyte, Trichophyton, Microsporum, and

Epidermophyton spp.) fungal infections to antifungal agents.

The standard discusses selection of antifungal agents; preparation of

antifungal stock solutions and dilutions for testing, implementation, and

interpretation of test procedures; and the purpose and implementation of

quality

control (QC) procedures.

This document replaces the first edition of the approved guideline, M38-A,

which was published in 2002. It includes the following updates:

* Supplemental material (QC data for mould isolates as well as

echinocandin testing guidelines) has been incorporated.

* Methods for testing dermatophyte moulds are provided based on a

series of consensus studies.

* Expanded list of relevant drug concentration to include

echinocandins and other suitable drug concentration ranges for testing

dermatophytes.

* Expanded recommendations on inoculum preparation of dermatophyte

species.

* Additional recommendations on incubation of Alternaria spp. and

echinocandins.

* Modified section on reading results to include new information on

echinocandins antifungal agents and MIC and MEC comparison.

* Expanded recommendations on reading results of itraconazole and new

triazoles.

This standard focuses on the fully defined synthetic medium RPMI-1640 for

testing of moulds because of the suitability of this test medium for antifungal

susceptibility testing of yeasts.

For additional information on CLSI or for further information regarding this

release, visit the CLSI website at _http://www.clsi.org_

(http://www.clsi.org/) or call +610.688.0100.

CLSI is a global, nonprofit, membership-based organization dedicated to

developing standards and guidelines for the health care and medical-testing

community. CLSI’s unique consensus process facilitates the creation of

standards

and guidelines that are reliable, practical, and achievable for an effective

quality system.

Clinical and Laboratory Standards Institute (CLSI)

Holm, Marketing Manager

Phone: +610.688.0100 ext. 129

E-mail: _aholm@..._ (mailto:aholm@...)

**************Wondering what's for Dinner Tonight? Get new twists on family

favorites at AOL Food.

(http://food.aol.com/dinner-tonight?NCID=aolfod00030000000001)